WO2008141511A8 - A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF - Google Patents

A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF Download PDF

Info

Publication number
WO2008141511A8
WO2008141511A8 PCT/CN2007/070044 CN2007070044W WO2008141511A8 WO 2008141511 A8 WO2008141511 A8 WO 2008141511A8 CN 2007070044 W CN2007070044 W CN 2007070044W WO 2008141511 A8 WO2008141511 A8 WO 2008141511A8
Authority
WO
WIPO (PCT)
Prior art keywords
tnfα
antibody
human anti
human
monoclonal antibody
Prior art date
Application number
PCT/CN2007/070044
Other languages
French (fr)
Chinese (zh)
Other versions
WO2008141511A1 (en
Inventor
Qingfa Liu
Original Assignee
Human Antibodomics Shanghai In
Qingfa Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Antibodomics Shanghai In, Qingfa Liu filed Critical Human Antibodomics Shanghai In
Priority to PCT/CN2007/070044 priority Critical patent/WO2008141511A1/en
Publication of WO2008141511A1 publication Critical patent/WO2008141511A1/en
Publication of WO2008141511A8 publication Critical patent/WO2008141511A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Abstract

A protein specifically binding to human TNFα (tumor necrosis factor α) is disclosed, i.e. human anti-TNFα monoclonal antibody derived from human B cells. The light and heavy chain of the antibody have the amino acid sequence as shown in SEQ ID NO: 3 and SEQ ID NO: 4, respectively. Also disclosed are the encoded sequences of the human anti- TNFα antibody, its Fab antibody and the peglated Fab antibody. The present invention further provides the uses of the antibodies in the preparation of the medicament for treatment of TNFα-related inflammation.
PCT/CN2007/070044 2007-05-22 2007-05-22 A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF WO2008141511A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070044 WO2008141511A1 (en) 2007-05-22 2007-05-22 A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2007/070044 WO2008141511A1 (en) 2007-05-22 2007-05-22 A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF

Publications (2)

Publication Number Publication Date
WO2008141511A1 WO2008141511A1 (en) 2008-11-27
WO2008141511A8 true WO2008141511A8 (en) 2009-07-09

Family

ID=40031397

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070044 WO2008141511A1 (en) 2007-05-22 2007-05-22 A HUMAN ANTI-TNFα MONOCLONAL ANTIBODY AND THE USE THEREOF

Country Status (1)

Country Link
WO (1) WO2008141511A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010105446A1 (en) * 2009-03-20 2010-09-23 上海宏源生物技术有限公司 A human anti-tumor necrosis factor alpha monoclonal antibody and use thereof
CN102167741B (en) * 2010-02-25 2014-05-14 上海百迈博制药有限公司 Fully human anti-TNF-alpha (Tumor Necrosis Factor-alpha) monoclonal antibody and preparation method as well as application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003267999B2 (en) * 2002-07-19 2010-03-11 Abbvie Biotechnology Ltd Treatment of TNFalpha related disorders
AU2003298816C1 (en) * 2002-12-02 2010-12-16 Amgen Fremont, Inc. Antibodies directed to Tumor Necrosis Factor and uses thereof
CN100393748C (en) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 Human tumour necrosin antibody, its preparation and medicinal composition
KR100772800B1 (en) * 2003-11-17 2007-11-01 주식회사유한양행 A variable region of the monoclonal antibody against a human tumor necrosis factor ? and a gene encoding the same
US7645450B2 (en) * 2004-12-29 2010-01-12 Yuhan Corporation Humanized antibody specific for tumor necrosis factor-alpha

Also Published As

Publication number Publication date
WO2008141511A1 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
WO2006068975A3 (en) Binding proteins specific for human matriptase
NZ603499A (en) Human cytomegalovirus neutralizing antibodies and uses thereof
NZ700473A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008017828A3 (en) Antibodies specific for human cd98 heavy antigen
NZ597466A (en) Recombinant anti-epidermal growth factor receptor antibody compositions
EP1578799B8 (en) Antibodies directed to tumor necrosis factor and uses thereof
TW200635945A (en) Antibodies against IL-13 receptor alpha 1 and uses thereof
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
PH12020551978A1 (en) Anti-interleukin-17a antibody, pharmaceutical composition thereof and use thereof
TW200745164A (en) Gene recombination antibodies composition
NZ595224A (en) Specific binding proteins and uses thereof
GEP20146050B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
JP2014518615A5 (en)
NZ587198A (en) Monoclonal antibodies against the rgm a protein and uses thereof
RS52484B (en) Antibodies to cd40
NZ703653A (en) Anti-fap antibodies and methods of use
EA201190132A1 (en) HUMANIZED ANTIBODIES, CONNECTING CD19, AND THEIR APPLICATION
EP3056511A3 (en) Il-1beta binding antibodies and fragments thereof
NZ599193A (en) Siglec 15 antibodies in treating bone loss-related disease
NZ594682A (en) Fully human antibodies specific to cadm1
NZ595792A (en) Antibodies specific to cadherin-17
EA032189B9 (en) Isolated human monoclonal antibodies against tissue factor pathway inhibitor (tfpi) and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07721667

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07721667

Country of ref document: EP

Kind code of ref document: A1